Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 259

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 259
---
 upon exercise or conversion of the Company’s equity awards, warrants, and other equity instruments convertible into common stock, as well as the respective exercise prices, if applicable in accordance with the terms of the instruments. No fractional shares of common stock were issued in connection with the 1:5 Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock. Unless otherwise noted, all references to numbers of shares of the Company’s common stock and per share information presented in these consolidated financial statements have been retroactively adjusted, as appropriate, to reflect the 1:5 Reverse Stock Split (and the 1:12 Reverse Stock Split in August 2024), including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. Other Events On January 8, 2025 and January 29, 2025, the Company issued 296,400shares and 88,800shares of common stock, respectively upon the exercise of 296,400and 88,800September 2024 Pre-Funded Warrants, respectively, resulting in aggregate cash proceeds to the Company of $ 1,926. On January 20, 2025, the Company issued a total of 15,809shares of common stock to certain executives and consultants, in settlement of the share-based portion of the 2024 performance bonuses as discussed in Note 10, based on the closing price of the Company’s common stock on January 2, 2025. Approximately 2,748shares were withheld to cover payroll tax withholdings. On January 28, 2025, the Company announced the approval of an Investigational Review Board (IRB) sanctioned Phase II clinical study. The study (NCT06656351) will evaluate the efficacy and safety of the tafenoquine for treating patients with a presumptive diagnosis of chronic babesiosis, the patient enrollment of which is expected to begin in the third quarter of 2025. There have been no other events or transactions during this time which would have a material effect on these consolidated financial statements. F-37 Up to 3,735,977 Shares of Common Stock 60 Degrees Pharmaceuticals, Inc. PRELIMINARY PROSPECTUS March 27, 2025 Part II INFORMATION NOT REQUIRED IN PROSPECTUS Item 13. Other Expenses of Issuance and Distribution. The following table indicates the expenses to be incurred in connection with the offering described in this registration statement,